Coloplast met expectations for growth for the 2006/07 financial year, reporting organic revenue growth of 10% against 8% last year. The company maintained the EBIT margin before non-recurring costs at 16% in a year dominated by extensive activity of integrating the acquired urology business, divesting businesses and relocating production to Hungary and China. EBIT was DKK 749m after non-recurring costs of DKK 552m, which included a goodwill writedown of DKK 283m (see enclosed PDF).
Recommended Reading
-
Interim financial results, 9M 2025/261 October 2025 - 30 June 2026 Coloplast delivered Q3 organic growth of 6% and 5% EBIT growth1 in constant currencies. Strong quarter in both Chronic Care ex....
Read More -
Coloplast announces changes to Executive Leadership Team Today, Coloplast announces two changes to the company’s Executive Leadership Team (ELT). The changes strengthen the leadership of Coloplast’s...
Read More